Symptoms, adverse events, and outcomes in the use of medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
10
11
2020
medline:
22
5
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
The objective of this scoping review is to map and identify the symptoms, adverse events, and outcomes in the use of medicinal cannabis in children and adolescents with autism spectrum disorder. Autism spectrum disorder is a neurodevelopmental disorder that impacts social communication and social interaction, and is associated with restrictive and repetitive behaviors and interests. Medicinal cannabis has become a potential area of interest for parents for the treatment of autism spectrum disorder symptoms in their children. There is some evidence that cannabinoids may be involved in autism spectrum disorder, laying a potential foundation for medicinal cannabis utility; however, previous reviews did not identify any clinical research on this topic. This scoping review will consider all published and unpublished studies that investigate the use of medicinal cannabis in autism spectrum disorder, where at least 50% of the participants have a diagnosis of autism spectrum disorder and at least 50% of the study population is 0 to 18 years of age, or where pediatric data are reported separately. Studies undertaken in any context (hospital or community) and in any geographic location will be included. We will search MEDLINE, Embase, CINAHL, PsycINFO, Web of Science, and Google Scholar, and the gray literature sources for studies. Two independent team members will screen titles and abstracts, review full texts for potential inclusion, and extract data for all studies. The results will be presented as a narrative synthesis and in tabular form.
Identifiants
pubmed: 33165173
pii: 02174543-202105000-00021
doi: 10.11124/JBIES-20-00001
doi:
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251-1258Informations de copyright
Copyright © 2021 JBI.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Public Health Agency of Canada. Autism spectrum disorder among children and youth in Canada 2018 [internet]. 2018 [cited 2019 Sep 16]. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/autism-spectrum-disorder-children-youth-canada-2018/autism-spectrum-disorder-children-youth-canada-2018.pdf.
American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA: American Psychiatric Association; 2013.
World Health OrganizationInternational Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Geneva: World Health Organization; 2016.
Anagnostou E, Zwaigenbaum L, Szatmari P, Fombonne E, Fernandez BA, Woodbury-Smith M, et al. Autism spectrum disorder: advances in evidence-based practice. Can Med Assoc J 2014;186 (7):509–519.
Reichow B. Overview of meta-analyses on early intensive behavioural intervention for young children with autism spectrum disorder. J Autism Dev Disord 2012;42:512–520.
Jesner O, Aref-Adib M, Coren E. Risperidone for autism spectrum disorders (review). Cochrane Database Syst Rev 2007;1000 (1):CD005040.
Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag R-J, Escobar R, Schacht A, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012;51 (7):733–741.
Rossingol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011;53 (9):783–792.
Fallah MS, Shaikh MR, Neupane B, Rusiecki, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child. Adolesc Psychopharmacol 2019;29 (3):168–180.
Hofer J, Hoffmann F, Bachmann C. Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: a systematic review. Autism 2017;21 (4):387–402.
Pawliuk C, Chau B, Rassekh SR, McKellar T, Siden H. Efficacy and safety of paediatric medicinal cannabis use: a scoping review [internet]. Paediatr Child Health 2020.
Tattrie J. Cannabis legalization in Canada [internet]. The Canadian Encyclopedia 2018.
Miles K. Marijuana-like chemical may help autism and fragile X syndrome symptoms [internet]. The Huffington Post. 2012 Sep 27 [cited 2019 Sep 16]. Available from: https://www.huffingtonpost.ca/2012/09/27/marijuana-chemical-autism-fragile-x_n_1920320.html.
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernadez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. J Am Med Assoc 2015;313 (24):2456–2473.
Elliott J, DeJean D, Clifford T, Coyle D, Potter B, Skidmore B, et al. Cannabis-based products for pediatric epilepsy: a systematatic review. Epilepsia 2019;60 (1):6–19.
Pertwee R. The diverse CB1 and CB2 receptor pharmacoogy of three cannabinoids: delta9-tetrahydrocannabinol, cannabidiol, and tetrahydrocannabivarin. Br J Pharmacol 2009;153 (2):199–215.
S Onaivi E, Benno R, Halpern T, Mehanovic M, Schanz N, Sanders C, et al. Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorder. Curr Neuropharmacol 2011;9 (1):209–214.
Kerr D, Downey L, Conboy M, Finn D, Roche M. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res 2013;249:124–132.
Zamberletti E, Marina G, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci 2017;18 (9):1916.
Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of anandamide-mediated endocanninoid signaling corrects autism-related social impairment. Cannabis Cannabinoid Res 2016;1 (1):81–89.
Siniscalo D, Sapone A, Giordano C, Cirillo A, Magistris L de, Rossi F, et al. Cannabinoid receptor type 2, but not type 1 is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord 2013;42 (11):2686–2695.
Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism 2018;9 (18):1–6.
Wong S, TE W. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics 2017;140 (5):e20171818.
Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 2019;9:200.
Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems - a retrospective feasibility study. J Autism Dev Disord 2019;49 (3):1283–1288.
Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs D, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 2019;9:1521.
Rieder MJ. Canadian Pediatic Society Drug Therapy and Hazardous Substances CommitteePosition statement: is the medical use of cannabis a therapeutic option for children? Paediatr Child Health 2016;21 (1):31–34.
Schweinsburg A, Nagel B, Schweinsburg B, Park A, Theilmann R, Tapert S. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res 2008;163 (1):40–51.
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370 (9584):319–328.
American Academy of PediatricsThe impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics 2019;135 (3):584.
Russell-George A, O’Reilly M, Lim N, Sigafoos J, Lancioni G. Cannabidiol (CBD) for autism spectrum disorders: a systematic review. PROSPERO 2019. CRD42019131354.
Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Aromataris E, Munn Z. Chapter 3: Systematic reviews of effectiveness. JBI, JBI Manual for Evidence Synthesis [internet]. Adelaide:2020.
Peters M, Godfrey C, McInerney P, Baldini Soares C, Kahlil H, Parker D. Aromataris E, Munn Z. Chapter 11: Scoping reviews [internet]. JBI, JBI Manual for Evidence Synthesis [internet]. Adelaide:2017.
Kohl C, McIntosh EJ, Unger S, et al. Online tools supporting the conduct and reporting of systematic reviews and systematic maps: a case study on CADIMA and review of existing tools. Environ Evid 2018;7:1–17.
Tricco A, Lillie E, Zarin W, O’Brien K, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169 (7):467–473.